For example, the 5-year overall survival (OS) rate of patients with non-small cell lung cancer (NSCLC) who received programmed cell death protein-1 (PD-1) inhibitors as second-line treatment rather than chemotherapy increased from 13% to 25% (Marei et al., 2023). Here, PDCD1 is linked to non-small cell lung carcinoma.